Condition: Atherosclerotic Cardiovascular Disease (ASCVD) · Elevated Lp(a) · Sponsor: Eli Lilly and Company
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Birmingham Clinical Research | Birmingham, Alabama, United States | — |
| Alliance for Multispecialty Research, LLC | Daphne, Alabama, United States | — |
| SEC Clinical Research | Dothan, Alabama, United States | — |
| Alliance for Multispecialty Research, LLC | Mobile, Alabama, United States | — |
| Mobile Heart Specialists | Mobile, Alabama, United States | — |
| Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC | Gilbert, Arizona, United States | — |
| Mercy Gilbert Medical Center | Gilbert, Arizona, United States | — |
| Sun City Clinical Research | Glendale, Arizona, United States | — |
| Elite Clinical Studies, LLC | Phoenix, Arizona, United States | — |
| Helios Clinical Research - Phoenix | Phoenix, Arizona, United States | — |
| Absolute Clinical Research | Phoenix, Arizona, United States | — |
| Clinical Research Institute of Arizona (CRI) - Sun City West | Sun City West, Arizona, United States | — |
+ 919 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.